Masterclass II Solving Real World Conundrum Application of Pivotal Trial Data to Patients with Challenging HCC
5:00 PM - Welcome and introduction
5:05 PM - Management of AEs and their monitoring in patients who are receiving Atezolizumab and Bevacizumab, with special emphasis on bleeding risk and irAEs.
5:15 PM - How do you treat HCC patients with liver dysfunction (Child Pugh B7-8)?
5:25 PM - How to treat HCC patients with severe macrovascular invasion
5:35 PM - How do you treat locally advanced HCC patients who have progressed on locoregional therapy
5:45 PM - Questions & Answers session
Details About the Webinar
Thursday, September 10, 2020 · 5:00 p.m.
Singapore (GMT +8:00)
Cost: Free
Add to calendar
WEBINAR ENDED
About the Speakers
Dr Kong Hwai Loong Chairperson
Dr Kong Hwai Loong is an Adjunct Associate Professor at National University of Singapore (NUS) and a visiting specialist in Medical Oncology at the National University Healthcare System (NUHS). Dr Kong was previously the Executive Director of the Biomedical Research Council (BMRC) and Deputy Managing Director for the Agency for Science, Technology and Research (A*STAR).
Dr Kong received his medical degree from NUS in 1988. He subsequently qualified in the Internal Medicine specialty in 1993 by earning his Master of Medicine (Internal Medicine) from NUS, as well as his Membership to the Royal College of Physician (UK). In 1998, he received his specialist qualification in Medical Oncology, and was elected to be a Fellow of the Academy of Medicine. He has a Masters in Business Administration from the Massachusetts Institute of Technology (MIT), USA, and was elected to be a Fellow of the Royal College of Physicians (Edinburgh) in 2004. He received his postgraduate medical fellowship training at the New York Hospital – Cornell Medical Centre between 1995 and 1997.
Dr Andrew Zhu Speaker
Dr. Andrew X. Zhu is Director of Jiahui International Cancer Center, Director Emeritus of Liver Cancer Research at Massachusetts General Hospital Cancer Center, and Professor of Medicine at Harvard Medical School. The major focus of his research is to develop more effective therapies for hepatocellular carcinoma (HCC) and cholangiocarcinoma. The second area is to develop novel molecular and imaging biomarkers for targeted therapeutics that have prognostic and/or predictive significance. The third area is to define and characterize known or novel genetic mutations in HCC and cholangiocarcinoma, assess their potential correlation with clinical outcomes and as therapeutic targets, and dissect the molecular mechanisms of drug resistance to targeted therapy.
Dr Hsu Chiun Speaker
Professor, Graduate Institute of Oncology, College of Medicine, National Taiwan University. Deputy director and visiting staff physician, Department of Oncology, National Taiwan University Hospital.
Dr. Hsu received his medical degree from College of Medicine, National Taiwan University in 1992 and was awarded his PhD by the Graduate Institute of Clinical Medicine at the same institution in 2004. He was a visiting scientist at Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center from 2004 to 2005. Dr. Hsu’s major research interest is clinical and translational research of new drug development for hepatobiliary cancers, and hepatitis B reactivation in cancer patients. He serves as a council member of the Asia-Pacific Primary Liver Cancer Expert (APPLE) meeting and a member of the European Society of Medical Oncology (ESMO) Faculty, gastro-intestinal tumour group.
Dr Choo Su Pin Speaker
Choo Su Pin is a medical oncologist who specialises in gastrointestinal cancers including colorectal, upper gastrointestinal, pancreas, hepatobiliary, peritoneal and anal cancers. She is a key opinion leader in hepatobiliary cancers.
Dr Choo is the current president of the Singapore Society of Oncology (SSO), a founding member of the SSO Cancer Immunotherapy Consortium and a council member of the Chapter of Medical Oncology, Academy of Medicine, Singapore. She is also a member of the Women For Oncology Committee, European Society of Medical Oncology.
Dr Toh Han Chong Speaker
Dr Toh Han Chong is Senior Consultant and Deputy Director, National Cancer Centre Singapore (NCCS). He is Associate Professor at the Cancer & Stem Cell Biology Program, Duke-NUS, and adjunct Principal Investigator, Singapore Immunology Network and Institute of Molecular and Cell Biology, A*STAR. Dr Toh graduated from the University of London, UK, with an Intercalated Bachelor of Science in ‘Infection and Immunity’ from St Mary’s Hospital Medical School and qualified as a medical doctor from University of Cambridge, United Kingdom. Dr Toh obtained his Fellowship of the Royal College of Physicians in 2003. He received his medical oncology fellowship training at the Singapore General Hospital, and at the Massachusetts General Hospital, Harvard Medical School, Boston, USA. He then completed a research fellowship in cancer immunotherapy at the Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA. Dr Toh is alumni of the Harvard Business School. Dr Toh is a recipient of the National Senior Clinician Scientist Award 2017 for translational research in cancer. He received the National Outstanding Clinician Scientist Award 2018. Dr Toh has published over 100 peer-review journal articles. Dr Toh is on the Asia-Pacific Primary Liver Cancer Expert (APPLE) council and is founding chairman of the Singapore Cancer Immunotherapy Consortium. He is on the European Society of Medical Oncology (ESMO) faculty for tumour immunology and immunotherapy.
